Adjuvant therapy of melanoma

Seminars in Cutaneous Medicine and Surgery

Volumn 22, Issue 1, 2003, Pages 55-67

  Geskin, Larisa ^a   Brown, C Romen ^b   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA2C INTERFERON; BCG VACCINE; BETA INTERFERON; CORYNEBACTERIUM PARVUM EXTRACT; DACARBAZINE; GAMMA INTERFERON; GANGLIOSIDE GM2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; LEVAMISOLE; MELANOMA VACCINE; SEMUSTINE; VINDESINE;

ACTIVE IMMUNIZATION; BCG VACCINATION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MELANOMA; PROPIONIBACTERIUM ACNES; REVIEW; SIDE EFFECT; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKINS; MELANOMA; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 0038370113     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2003.50005     Document Type: Review

References (90)

1. Zarour HM, Maillere B, Brusic V, et al: NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1 and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62:213-218, 2002
2. Balch CM, Soong S, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma staging sytem. J Clin Oncol 19:3622-3634, 2001
3. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88:1484-1491, 2000
4. Kirkwood J: Adjuvant IFN alpha2 therapy of melanoma: Comment. Lancet 351:1905-1910, 1998
5. Blomgren H, Cantell K: Interferon therapy in Hodgkin's disease: a case report. Acta Med Scand 199:527-532, 2002
6. Merigan T, Silora K, et al: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449-1453, 1978
7. Idestrom K, Cantell K, et al: Interferon therapy in multiple myeloma. Acta Med Scand 205:149-154, 1979
8. Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399-405, 1980
9. Fidler I: Angiogenesis and cancer metastasis. Cancer J 6:S134-141, 2000
10. Horoszewicz JS, Leong SS, Ito M, et al: Human fibroblast interferon in human neoplasia: Clinical and laboratory study. Cancer Treat Report 62:1899-1906, 1978
11. Dreau D, Foster M, et al: Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol 12:241-251, 2000
12. Liekens S, Clercq E: Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 61:253-270, 2001
13. Carson W: Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin Canc Res 4:2219-2228, 1998
14. Kirkwood JM, Richards T, Zarour H, et al: Immuno-modulatory effects of high- and low-dose IFNα2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101-1112, 2002
15. Borden E, Lindner D, et al: Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 10:125-144, 2000
16. Kirkwood JM, Bender C, Agarwala SS, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002
17. Kirkwood JM, Ernstoff MS: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 12:7-12, 1985
18. Kirkwood JM, Ernstoff MS, Davis CA, et al: Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103:32-36, 1985
19. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783, 1995
20. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
21. Kirkwood, JM, Ibrahim, JG, Sondak, VK, et al: High- and low- dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9090: Classic Papers and Current Comments. J Clin Oncol 7:550-564, 2002
22. Kirkwood, JM, Ibrahim, J, Lawson, DH, et al: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696: Classic Papers and Current Comments. J Clin Oncol 7:576-582, 2002
23. Kirkwood, JM, Ibrahim, JG, Sosman, JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801: Classic Papers and Current Comments. J Clin Oncol 7:565-575, 2002
24. Kirkwood, JM, Strawderman, MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684: Classic Papers and Current Comments. J Clin Oncol 7:535-549, 2002
25. Kirkwood JM, Ibrahim JG, Sondak VK, et al: Interferon alfa-2a for melanoma metastases (letter). Lancet 359:978-979, 2002
26. Islam M, Frye R, Richards T, et al: Differential effect of IFN alpha-2b on the cytochrome P450 enzyme system: A potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 8:2480-2487, 2002
27. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
28. Cascinelli N, Bufalino R, Morabito A, et al: Results of adjuvant interferon study in WHO melanoma programme. Lancet 343:913-914, 1994
29. Grob JJ, Dreno B, de la Salmonière P, et al: Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1-5 mm without clinically detectable node metastases. Lancet 351:1905-1910, 1998
30. Pehamberger H, Soyer P, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425-1429, 1998
31. Hancock BW, Wheatley K, Harrison G, et al: Aim high-adjuvant interferon in melanoma (high risk), a United Kingdon Co-Ordinating Committee on Cancer Research (UKCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. Proc ASCO 20:349a, 2002 (abstr)
32. Cameron D, Cornbleet M, et al: Adjuvant interferon alpha 2b in high-risk melanoma: The Scottish Study. Br J Cancer 84:1146-1149, 2001
33. Gray RJ, Pockaj BA, Kirkwood JM: An update on adjuvant interferon for melanoma. Cancer Control 9:16-21, 2002
34. Kilbridge KL, Cole BF, Kirkwood JM, et al: Quality-of-life adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20:1311-1318, 2002
35. Lens MB, Dawes M: Interferon alfa therapy for malignant melanoma: A systemic review of randomized controlled trials. J Clin Oncol 20:1818-1825, 2002
36. Meyskens FL, Jr: Thinking about cancer causality and chemoprevention. Commentary. J Nat Cancer Inst 80:1278-1281, 1988
37. Brooks C: Reversible induction of natural killer cell activity in cloned muring cytotoxic T lymphocytes. Nature 305:155-158, 1983
38. Malkovsky M, Loveland B, et al: Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature 325:262-265, 1987
39. Rosenberg SA, Mule JJ, Spiess PJ, et al: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169-1188, 1985
40. Rayner A, Grimm E, et al: Lymphokine-activated killer (LAK) cells: Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55:1327-1333, 1985
41. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
42. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic melanoma. N Engl J Med 313:1485-1492, 1985
43. Rosenberg SA, Lotze MT, Mulé JJ: New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108:853-864, 1988
44. Rosenberg S, Yannelli J, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Cancer Inst 86:1159-1166, 1994
45. Dudley M, Wunderlich J, Nishimura M, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-373, 2001
46. Castello G, Comella P, et al: Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res 3:43-49, 1993
47. Eton O, Talpaz M, Lee KH, et al: Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a. Cancer 77:893-899, 1996
48. Nagai H, Hara I, et al: Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 115:1059-1064, 2000
49. Gallagher R: Tagging T cells: TH1 or TH2? Science 275:1615, 1997
50. Rissoan M, Soumelis V, et al: Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186, 1999
51. Enk AH, Jonuleit H, Saloga J, et al: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316, 1997
52. Veenstra K, Jonak Z, et al: IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma. J Immunol 168:2282-2287, 2002
53. Gollob J, Mier J, et al: Clinical use of systemic IL-12 therapy. Canc Chemother Biol Response Modif 19:353-369, 2001
54. Shurin M, Kirkwood J, et al: Cytokine-based therapy for melanoma: Pre-clinical studies. Forum (Genova) 10:204-226, 2000
55. Lu L, Hsieh M, et al: Generation of DC from mouse spleen cell cultures in response to GM-CSF immunophenotypic and functional analyses. Immunology 84:127-134, 1995
56. Spitler LE, Grossbard ML, Ernstoff MS, et al: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor (GM-CSF). J Clin Oncol 18:1614-1621, 2000
57. Morton D: Immunological studies with human neoplasms. J Reticuloendothel Soc 10:137-160, 1971
58. Nathanson L: Regression of intradermal malignant melanoma after intralesional injection of mycobacterium bovis strain BCG. Cancer Chemother Rep 56:659-665, 1972
59. Bornstein R, Mastrangelo M, et al: Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr 39:213-220, 1973
60. Pinsky CM, Hirshaut Y, Wanebo HJ, et al: Randomized trial of bacillus Calmette-Guerin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma. Ann NY Acad Sci 49:1079-1084, 1982
61. Morton D, Eilber F, et al: Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust N Z J Surg 48:49-52, 1978
62. Paterson AHG, Willans D, Jerry LM, et al: Malignant melanoma (stage 1): A clinical trial of adjuvant BCG immunotherapy, in Bonadonna G, Mathé G, Salmon SE (eds): Recent Results in Cancer Research, vol 68. Berlin, Springer-Verlag, 1979, pp 387-392
63. Wood WC, Cosimi AB, Carey RW, et al: Randomized trial of adjuvant therapy for "high-risk" primary malignant melanoma. Surgery 83:677-681, 1978
64. Plesnicar S, Rudolf Z: Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma. Cancer 50:1100-1106, 1982
65. Paterson AH, Willans DJ, Jerry LM, et al: Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc 131:744-748, 1984
66. Castel T, Estape J, Viñolas N, et al: Adjuvant treatment in stage I and II malignant melanoma: A randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica 183:25-30, 1991
67. Cunningham TJ, Schoenfeld D, Nathanson L, et al: A controlled ECOG study of adjuvant therapy in patients with stage I and II malignant melanoma. In: Jones SE, Salmon SE. Adjuvant Therapy of Cancer II: Proceedings of the Second International Conference on the Adjuvant Therapy of Cancer. New York, NY, Grune & Stratton, 1979, pp 507-517
68. Balch CM, Smalley RV, Bartolucci AA, et al: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): Prognostic factors analysis and preliminary results of immunotherapy. Cancer 49:1079-1084, 1982
69. Jacquillat C, Banzet P, Maral J: Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma. Recent Results in Cancer Research. Heidelberg, Springer-Verlag, 1982, pp 254-258
70. Hilal EY, Pinsky CM, Hirshaut Y, et al: Surgical adjuvant therapy of malignant melanoma with Corynebacterium Parvum. Cancer 48:245-251, 1981
71. Stevenson H, Green I, et al: Levamisole: Known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 9:2052-2066, 1991
72. Loutfi A, Shakr A, Jerry M, et al: Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous melanoma. Clin Invest Med 10:325-328, 1987
73. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 9:736-740, 1991
74. Tatsumi T, Kierstead L, Ranieri E, et al: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628, 2002
75. Ranieri E, Kierstead LS, Zarour H, et al: Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading. Immunological Investigations 29:121-125, 2000
76. Comis RL: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Report 60:165-176, 1976
77. Luikart SD, Kennealey GT, Kirkwood JM: Randomized phase III trial of vinblastine, bleomycin and cis-dichlorodiammine-platinum versus dacarbazine in malignant melamona. J Clin Oncol 158:238-242, 1984
78. Middleton MR, Gore M, Tilgen W, et al: A randomized, phase III study of temozolomide (TMZ) versus dacarbazine (DTIC) in the treatment of patients with advanced, metastatic melanoma. J Clin Oncol 18:158-166, 2000
79. Hill IGJ, Moss SE, Golomb FM, et al: DTIC and combination therapy for melanoma: DTIC (NSC 45388) surgical adjuvant study COG protocol 7040. Cancer 47:2556-2562, 1981
80. Veronesi U, Adamus J, Aubert C, et al: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913-916, 1982
81. Fisher RI, Terry WD, Hodes RJ, et al: Adjuvant immunotherapy or chemotherapy for malignant melanoma: Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 61:1267-1277, 1981
82. Pectasides D, Alevizakos N: Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II milignant melanoma. Am J Clin Oncol 17:55-59, 1994
83. Knost JA, Reynolds V, Greco FA, et al: Adjuvant chemoimmunotherapy stage I/II malignant melanoma. J Surg Oncol 9:165-170, 1982
84. Sterchi J, Wells H: A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma: an interim report. Cancer 55:707-712, 1985
85. Karakousis CP, Didolkar MS, Lopez R, et al: Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Reports 63:1739-1743, 1979
86. Kerin MJ, Gillen P, Monson JR, et al: Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma. Eur J Surg Oncol 21:548-550, 1995
87. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
88. Cole BF, Gelber RD, Kirkwood JM, et al: A quality-oflife-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study (E1684). J Clin Oncol 14:2666-2673, 1996
89. Livingston PO, Wong GYC, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
90. Kirkwood JM, Ibrahim J, Sondak VK, et al: Use and abuse of statistics in evidence-based medicine (letter). J Clin Oncol 20:4122-4123, 2002